SCHEMBL597116

SCHEMBL597116

C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3cccc(Cl)c3)n[nH]c2C1(C)C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PRKCB P05771 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL597140 0.92 PRKCB (1.00) PRKCB
SCHEMBL596893 0.92 PRKCB (0.86) PRKCB
SCHEMBL596362 0.91 PRKCB (1.00) PRKCB
SCHEMBL597658 0.91 PRKCB (1.00) PRKCB
SCHEMBL596914 0.90 PRKCB (1.00) PRKCB
SCHEMBL598986 0.90 PRKCB (1.00) PRKCB
SCHEMBL14038609 0.90 PRKCB (1.00) PRKCB
SCHEMBL598501 0.90 PRKCB (1.00) PRKCB
SCHEMBL597405 0.89 PRKCB (1.00) PRKCB
SCHEMBL598242 0.89 PRKCB (1.00) PRKCB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2195321-B1 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES AS INHIBITORS OF PROTEIN KINASE C PFIZER (US) 2016-10-19 EP disclosed
EP-2195321-B1 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES AS INHIBITORS OF PROTEIN KINASE C PFIZER (US) 2016-10-19 EP disclosed
US-8999981-B2 3-amido-pyrrolo[3,4-C]pyrazole-5(1H, 4H,6H) carbaldehyde derivatives PFIZER INC. (US) 2015-04-07 US disclosed
US-8999981-B2 3-amido-pyrrolo[3,4-C]pyrazole-5(1H, 4H,6H) carbaldehyde derivatives PFIZER INC. (US) 2015-04-07 US disclosed
US-20120108588-A1 NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES PFIZER, INC. (US) 2012-05-03 US disclosed
US-20120108588-A1 NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES PFIZER, INC. (US) 2012-05-03 US disclosed
US-8114871-B2 3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives PFIZER INC. (US) 2012-02-14 US disclosed
US-8114871-B2 3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives PFIZER INC. (US) 2012-02-14 US disclosed
US-8114871-B2 3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives PFIZER INC. (US) 2012-02-14 US disclosed
US-20100249128-A1 NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H,4H,6H) CARBALDEHYDE DERIVATIVES PFIZER INC. 2010-09-30 US disclosed
US-20100249128-A1 NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H,4H,6H) CARBALDEHYDE DERIVATIVES PFIZER INC. 2010-09-30 US disclosed
US-20100249128-A1 NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H,4H,6H) CARBALDEHYDE DERIVATIVES PFIZER INC. 2010-09-30 US disclosed
WO-2008125945-A2 3-AMIDO-PYRROLO [3, 4-C] PYRAZOLE-5 (1H, 4H, 6H) CARBALDEHYDE DERIVATIVES AS INHIBITORS OF PROTEIN KINASE C PFIZER INC. (US) 2008-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249128-A1 NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H,4H,6H) CARBALDEHYDE DERIVATIVES INSR, IAPP, PYCR1 PRKCB 2011/4885
US-20120108588-A1 NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES INSR, IAPP, PYCR1 PRKCB 2011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.